7C Gold urinary assay of neural thread protein in Alzheimer's disease

Alzheimer's Reports

Volumn 3, Issue 3, 2000, Pages 155-159

  Fitzpatrick, Judith ^a,b   Munzar, Michael ^a   Focht, Maggie ^a   Bibiano, Riza ^a   Averback, Paul ^a  

^a Serex Incorporated   (United States)

^b Nymox Corporation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23044521115     PISSN: 14616130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. th Ed. American Psychiatrie Association, Washington DC.
2. Arai H, Terajima M, Miura M étal. (1995). Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. AnnNeurol 38,649-652.
3. Bowler JV, Munoz DG, Merskey H and Hachinski V (1998). Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. JNeurol NeurosurgPsychiatr§4,18-24.
4. Burns A, Luthert P, Levy R étal. (1990). Accuracy of clinical diagnosis of Alzheimer's disease. aM/301,1026.
5. Chong JK, Cantrell L, Husain M étal. (1992). Automated microparticle enzyme immunoassay for neural thread protein in cerebrospinal fluid from Alzheimer's disease patients. JClin Lab Ana/6,379383.
6. Corey-Bloom J, Thai LJ, Galasko D et al. (1995). Diagnosis and evaluation of dementia. Neurology, 211-218.
7. de la Monte SM, Ozturk M and Wands JR (1990). Enhanced expression of an exocrine pancreatic protein in Alzheimer's disease and the developing human brain. J'ClinInvestfà, 1004-1013.
8. de la Monte SM and Wands JR (1992). Neuronal thread protein overexpression in brains with Alzheimer's disease lesions. JNeurol Sc/113,152-164.
9. de la Monte SM, Volicer L, Hauser SL and Wands JR (1992). Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann NeurolVl, 733-742.
10. de la Monte SM, Carlson Rl, Brown NV and Wands JR (1996a). Profiles of neuronal thread protein expression in Alzheimer's disease. J Neuropathol Exp NeurolK, 1038-1050.
11. de la Monte SM, Xu YY and Wands JR (1996b). Modulation of neuronal thread protein expression with neuritic sprouting: relevance to Alzheimer's disease. JNeuro/Scitel, 26-35.
12. de la Monte SM, Xu YY, Huchins GM and Wands JR (1996c). Developmental patterns of neuronal thread protein gene expression in Down syndrome. JNeurol'Sfc/135,118-125.
13. de la Monte SM, Ghanbari K, Frey WH étal. (1997). Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41 kD protein in cerebrospina! fluid. JClin Iwesf 100, 3093-3104.
14. de la Monte SM, Ghanbari H, Ghanbari K étal. (1999). AD7C-NTP biomarker for Alzheimer's disease. Alz Rep 2,327-332.
15. Fleming KC, Adams AC and Peterson RC (1995). Dementia: Diagnosis and evaluation. Mayo Clin Prod, 1093-1107.
16. Gilleard CJ, Kellett JM, Coles JA étal. (1992) The St. George's dementia bed investigation study. Acta Psychiatr Scand&S, 264-269.
17. Growdon JH, Graefe K, Tennis M et al. (1997). Pupil dilation to tropicamide is not specific for Alzheimer's disease. ArchNeurol 54,841-844.
18. Growdon JH, Davies R Oilman S étal. (1998). Consensus report of the working group on: "Molecular and Biochemical Markers of Alzheimer's disease". Neurobioi'Aging'19,109-116.
19. Hanley JA and McNeil BJ (1983). A method of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology4&, 839-843.
20. Iwatsubo T (1998). Amyloid βprotein in plasma as a diagnostic marker for Alzheimer's disease. NeurobioiAging, 161-163.
21. Jensen M, Basun H and Lannfelt L (1995). Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lettfà, 189-191.
22. Jorst BC and Grossberg GT (1995). The natural history of Alzheimer's disease: a brain bank study. JAm Geriatr Soc43, 12481255.
23. Kahle, PJ, Jakowec M, Teipel SJ etal. (2000). Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology «, 1498-1504.
24. KennardML, FeldmanH,YamadaTandJefferiesWA(1996). Serum levels of the iron binding protein P-97 are elevated in Alzheimer's disease. NatMed2,1230-1235.
25. McKhann G, Drachmen D, Folstein M et al.. (1984). Clinical diagnosis of Alzheimer's disease: report of the NI NCOS - ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34,939-944.
26. Mendez M, Mastri AR, Sung JH and Frey WH (1992). Clinically diagnosed Alzheimer's disease: neuropathologic findings in 650 cases. Alzheimer Dis Assoc DisordS, 35-43.
27. Molsa PK, Paljarvi L, Rinne JO etal. (1985). Validity of clinical diagnosis in dementia: a prospective clinicopathological study. J Neurol Neurosurg' PsychiatrA&, 1085-1090.
28. Motter R, Vigo-Pelfrey C, Kholodenko D étal. (1995). Reduction of βamyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. AnnNeurol"&, 643-648.
29. Munroe WA, Southwick PC, Chang L étal. (1995). Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Science'15, 207-217.
30. Myers RH, Schaefer EJ, Wilson PWF etal. (1996). Apolipoprotein E E4 association with dementia in a population-based study: the Framingham study. Neurologyfà, 673-677.
31. Nitsch RM, Rebeck W, Deng M et al. (1995). Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotypes. AnnNeuroiyi, 512-518.
32. Ozturk M, de la Monte SM, Gross J and Wands JR (1989). Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain. ProcNat/AcadSet USA 86, 419-423.
33. Pirttila T, Kirn KS, Mehta PD etal. (1994). Soluble amyloid-β-protein in the cerebrospinal fluid of patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sciïl, 90-95.
34. Pirtilla T, Mehta PD, Soininen H etal. (1996). Cerebrospinal fluid concentrations of soluble amyloid β-protein and apolipoprotein E in patients with Alzheimer's disease. Arch Neuroltt, 189-193.
35. Risse SC, Raskind MA, Nochlin D. etal.. (1990). Neuropathological findings in patients with clinical diagnoses of probable Alzheimer's disease. Am JPsychiatrMiï, tt-W2.
36. Rocca WA, Amaducci LA and Schoenberg BS (1986). Epidemiology of clinically diagnosed Alzheimer's disease. AnnNeurol§, 415424.
37. Scinto LFM, Daffner KR, Dressler D et al. (1994). A potential noninvasive neurobiologie test for Alzheimer's disease. Science 266,1051-1054.
38. TamaokaA, Fukushima T, Sawamura N etal. (1996). Amyloid β protein in plasma from patients with sporadic Alzheimer's disease. «//Vewo/St/151, 65-68.
39. Tata RE, FrankAand HernanzA(1995). Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. JNeurolNeurosurgPsychiatr, 280-283.
40. Van Gool WA, Kuiper MA, Wolstra GJM etal. (1995). Concentrations of amyloid β-protein in cerebrospinal fluid of patients with Alzheimer's disease. AnnNeuroiyi, 277-279.
41. Vigo-Pelfrey C, Seubert P, Barbour R etal. (1995). Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neuro/ogyte, 778-793.